Stock Analysis
Indian Exchange: Awfis Space Solutions And 2 Stocks That May Be Trading Below Estimated Value
Reviewed by Simply Wall St
The Indian market has shown strong performance with a 1.0% increase over the last week and a remarkable 39% rise over the past year, while earnings are projected to grow by 17% annually. In such a robust environment, identifying stocks that may be trading below their estimated value can offer potential opportunities for investors seeking to capitalize on undervalued assets.
Top 10 Undervalued Stocks Based On Cash Flows In India
Name | Current Price | Fair Value (Est) | Discount (Est) |
Apollo Pipes (BSE:531761) | ₹553.65 | ₹1106.50 | 50% |
Titagarh Rail Systems (NSEI:TITAGARH) | ₹1133.00 | ₹2144.97 | 47.2% |
RITES (NSEI:RITES) | ₹304.50 | ₹516.92 | 41.1% |
IOL Chemicals and Pharmaceuticals (BSE:524164) | ₹433.00 | ₹762.32 | 43.2% |
Vedanta (NSEI:VEDL) | ₹486.70 | ₹905.55 | 46.3% |
Patel Engineering (BSE:531120) | ₹54.41 | ₹91.98 | 40.8% |
Orchid Pharma (NSEI:ORCHPHARMA) | ₹1368.45 | ₹2142.32 | 36.1% |
Tarsons Products (NSEI:TARSONS) | ₹417.25 | ₹707.09 | 41% |
Manorama Industries (BSE:541974) | ₹923.80 | ₹1665.51 | 44.5% |
Strides Pharma Science (NSEI:STAR) | ₹1630.95 | ₹2704.30 | 39.7% |
Underneath we present a selection of stocks filtered out by our screen.
Awfis Space Solutions (NSEI:AWFIS)
Overview: Awfis Space Solutions Limited offers flexible workspace solutions in India with a market cap of ₹53.02 billion.
Operations: The company's revenue is primarily derived from Co-Working Space on Rent and Allied Services at ₹6.65 billion, followed by Construction and Fit-Out Projects contributing ₹2.29 billion.
Estimated Discount To Fair Value: 14.5%
Awfis Space Solutions, trading at ₹755.2, is undervalued relative to its estimated fair value of ₹883.32. Despite a volatile share price recently, the company shows promising revenue growth forecasts of 28.8% annually, surpassing market expectations. Earnings are projected to grow significantly by 89.27% per year and become profitable within three years, indicating robust cash flow potential. Recent business expansions in GIFT City and Pune enhance its strategic positioning in India's flexible workspace market.
- Our expertly prepared growth report on Awfis Space Solutions implies its future financial outlook may be stronger than recent results.
- Get an in-depth perspective on Awfis Space Solutions' balance sheet by reading our health report here.
Strides Pharma Science (NSEI:STAR)
Overview: Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products across various regions including Africa, Australia, North America, Europe, Asia, India, and internationally with a market cap of ₹144 billion.
Operations: The company's revenue is primarily generated from its Pharmaceutical Business (excluding Bio-Pharmaceutical Business), amounting to ₹42.09 billion.
Estimated Discount To Fair Value: 39.7%
Strides Pharma Science, priced at ₹1630.95, is trading 39.7% below its estimated fair value of ₹2704.3, reflecting potential undervaluation based on cash flows. The company is forecasted to achieve profitability in the next three years with earnings growth projected at 99.48% annually, outpacing market averages. Recent debt redemption actions have reduced outstanding non-convertible debentures significantly to ₹242 million, potentially improving financial flexibility and supporting future growth prospects.
- In light of our recent growth report, it seems possible that Strides Pharma Science's financial performance will exceed current levels.
- Dive into the specifics of Strides Pharma Science here with our thorough financial health report.
Titagarh Rail Systems (NSEI:TITAGARH)
Overview: Titagarh Rail Systems Limited manufactures and sells freight and passenger rail systems in India and internationally, with a market cap of ₹152.59 billion.
Operations: The company's revenue is derived from two main segments: Passenger Rail Systems, contributing ₹3.32 billion, and Freight Rail Systems (including shipbuilding, bridges, and defense), generating ₹35.14 billion.
Estimated Discount To Fair Value: 47.2%
Titagarh Rail Systems, trading at ₹1133, is significantly undervalued with a fair value estimate of ₹2144.97. Despite recent shareholder dilution, the company shows promising growth potential with forecasted revenue and earnings growth rates of 25.7% and 30.1% per year respectively, outpacing the Indian market averages. Recent strategic adjustments in wagon orders with Indian Railways have optimized capacity utilization while avoiding penalties, enhancing operational efficiency and cash flow management.
- Our earnings growth report unveils the potential for significant increases in Titagarh Rail Systems' future results.
- Click here to discover the nuances of Titagarh Rail Systems with our detailed financial health report.
Turning Ideas Into Actions
- Delve into our full catalog of 26 Undervalued Indian Stocks Based On Cash Flows here.
- Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.
- Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.
Interested In Other Possibilities?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About NSEI:STAR
Strides Pharma Science
Develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally.